Photo Credit: Nemes Laszlo
The following is a summary of “Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia,” published in the December 2023 issue of Hematology by Cui et al.
Venetoclax (VEN) and azacitidine (AZA) offer hope for acute myeloid leukemia (AML) patients, but high toxicity often necessitates dose reduction, limiting treatment effectiveness.
Researchers performed a retrospective study to analyze the efficacy and safety of a reduced venetoclax dosage in first-line AML treatment.
They conducted an observational study analyzing the characteristics and outcomes of newly diagnosed AML patients who received 100 mg VEN combined with AZA for 14 days at their institution.
The results showed 36 patients with a median age at diagnosis of 64 years. After a median follow-up of 15 months (range 4–29), the overall cohort exhibited a median OS of 17 months (4–29) and progression-free survival (PFS) of 12 months (1–28). The ORR was 69.4%, with a CRc rate of 66.7%. Subgroup analysis indicated higher response rates for NPM1 mutations and FAB-M5 subtype, while an adverse ELN risk group predicted an inferior response. Negative impacts on PFS were observed with ASXL1, NPM1, and IDH1/2 mutations.
Investigators concluded that reduced-dose venetoclax in AML yielded similar survival and response rates to standard doses, suggesting a possible optimization strategy for VEN-based regimens.
Source: tandfonline.com/doi/full/10.1080/16078454.2023.2293512